Drug intelligence / Profile preview

ABS-004

Development stage: Preclinical
Lead developer: Alpha Biomedical
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies

Overview

ABS-004 is an investigational natural killer (NK) cell therapy being developed by Alpha Biomedical for the treatment of liver cancer. As an adoptive cell therapy, it utilizes NK cells, which are innate immune effector cells capable of recognizing and killing tumor cells through the release of perforins and granzymes or by inducing apoptosis via death receptor pathways. The program is currently in the preclinical stage of development and aims to leverage the innate cytotoxic potential of NK cells to provide a rapid and effective response against malignant liver cells.

Targets

IL11 (Interleukin-11)BAFF (Tumor necrosis factor ligand superfamily member 13B)MYC (MYC proto-oncogene protein)TNFSF13 (APRIL)

Beyond the preview

Go deeper on ABS-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABS-004.

Explore the full profile